Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO. RETEVMO® (selpercatinib) capsules, for oral useRETEVMO® (selpercatinib) tablets, for oral useInitial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
- generic_name
- selpercatinib
- product_names
- selpercatinib
- ndc
- 0002-3977, 0002-3977-60, 0002-2980, 0002-2980-60, 0002-2980-26, 0002-5340, 0002-5340-60, 0002-6082, 0002-6082-60, 0002-6120, 0002-6120-60, 0002-5562, 0002-5562-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en